Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 7/20 | 0.34 |
| ▸ | APP | P05067 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006186 | 0.85 | KDM4E (0.35) | KDM4EALDH1A1POLB | |
| SCHEMBL27877845 | 0.84 | ADK (0.34) | ADKAPP | |
| SCHEMBL1006671 | 0.81 | HPGDS (0.41) | ALDH1A1POLBABL1BCRMAPT | |
| SCHEMBL1527521 | 0.77 | MAPT (0.34) | ALDH1A1POLBMAPT | |
| SCHEMBL2230401 | 0.76 | FFAR1 (0.37) | KDM4EALDH1A1POLBABL1BCR | |
| SCHEMBL1007402 | 0.76 | S1PR3 (0.41) | — | |
| SCHEMBL1010354 | 0.74 | GRM5 (0.46) | ADKKDM4EALDH1A1POLB | |
| SCHEMBL1008135 | 0.74 | S1PR3 (0.40) | KDM4EALDH1A1POLBMAPT | |
| SCHEMBL1008800 | 0.74 | RECQL (0.34) | ALDH1A1EGFRMAPT | |
| SCHEMBL1007852 | 0.72 | KDM4E (0.34) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9408907-B2 | Homogenous suspension of immunopotentiating compounds and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-09 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | disclosed |
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | disclosed |
| US-20130122042-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | ADK 1927/4885APP 2848/4885KDM4E 1503/4885 |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | LY96, TLR3, GABRA4 | ADK 4552/4885APP 657/4885KDM4E 2163/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | ADK 1927/4885APP 2848/4885KDM4E 1503/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | ADK 3736/4885APP 1282/4885KDM4E 3767/4885 |
| US-20130122042-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | ADK 3736/4885APP 1282/4885KDM4E 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.